Scope of indications for Evantumumab/Carestream

Amivantamab is a bispecific antibody that targets EGFR (epidermal growth factor receptor) and MET receptors and is mainly used to treat non-small cell lung cancer (NSCLC). Unlike traditional targeted therapy drugs, evantumumab can more effectively overcome certain resistance mechanisms, especially resistance problems caused by EGFR mutations and MET amplification, by acting on two key receptors at the same time.

The indications for evantumumab include the following aspects:

1. Combined with lazertinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutation. For such patients, the combination of evantumumab and lazetinib can improve the therapeutic effect and delay disease progression. EGFR exon 19 deletion and exon 21 L858R mutation are common driver mutations in NSCLC. Lazertinib, as a new EGFR inhibitor, can provide effective treatment for these mutations, while evantumumab further enhances the anti-tumor effect through the inhibition of MET receptors.

2. In combination with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. EGFR exon 20 insertion mutation is a special type of mutation, for which conventional EGFR inhibitors have limited efficacy. Evantumumab combined with chemotherapy (carboplatin and pemetrexed) provides a new treatment option for these patients and helps improve the clinical prognosis of patients.

3. As a monotherapy, it is suitable for patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations and whose disease has progressed during or after platinum-based chemotherapy. For patients whose disease has progressed after standard platinum-based chemotherapy, evantumumab, as a single agent, is effective in inhibiting tumor growth, especially in patients with EGFR exon 20 insertion mutations. Since such mutations are difficult to control through traditional EGFR targeted therapy, the introduction of evantumumab brings new hope to these patients.

Reference materials:https://www.rybrevant.com/